Holen Sie sich die Stockscreener-App
11.84
0.75%
-0.09
Schlusskurs vom Vortag:
$11.93
Offen:
$11.93
24-Stunden-Volumen:
1.30M
Relative Volume:
0.73
Marktkapitalisierung:
$856.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$84.01M
KGV:
13.83
EPS:
0.856
Netto-Cashflow:
$-101.16M
1W Leistung:
+20.94%
1M Leistung:
+24.50%
6M Leistung:
+1.28%
1J Leistung:
+205.94%
1-Tages-Spanne:
$11.37
$11.99
1-Wochen-Bereich:
$10.50
$12.16
52-Wochen-Spanne:
$3.435
$17.65
Omeros Corp Stock (OMER) Company Profile
Firmenname
Omeros Corp
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
11.84 | 820.74M | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corp Aktie (OMER) Neueste Nachrichten
H.C. Wainwright reiterates Omeros stock rating on rival trial miss By Investing.com - Investing.com Canada
Omeros Corp (OMER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Omeros Corp (OMER) Institutional Confidence - TradingKey
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty - GuruFocus
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights - Stocktwits
OMER | Omeros Corporation FinancialsIncome Statement - Quiver Quantitative
Omeros Corp (OMER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Omeros Corp (OMER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Omeros Corporation For: 24 July By Investing.com - Investing.com South Africa
OMER|Omeros Corp|Price:11.340|Chg%:+1.550 - TradingKey
Omeros Corp (OMER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Omeros Corp (OMER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - GlobeNewswire Inc.
OMER6080787 Bond Profile — Key Metrics - TradingView
Omeros repurchases $14.5M of 9.50% convertible notes, total retirements $30.5M - TradingView
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros CorporationOMER - PR Newswire
EMA Committee Rejects Marketing Authorization for Omeros Corp Antibody Narsoplimab - sekbernews.id
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return - Yahoo Finance
Omeros Corporation Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? - AOL.com
Omeros shares drop 19% after EMA rejects narsop... - Pluang
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments - Seeking Alpha
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now? - Insider Monkey
Omeros Corporation Files SEC Form 8-K for Other Events – Nasdaq: OMER, July 2026 - Minichart
Omeros to repurchase $16M of 9.50% notes, may buy up to $14.5M more - TradingView
Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt - Stock Titan
Omeros Corporation Reports First Quarter 2026 Financial Results - The National Law Review
Omeros stock drops 19% after EU rejects key dru... - Pluang
OMEROS CORP (OMER) Stock Chart - ChartMill
Omeros stock crashes on regulatory setback: Buy the dip? - MSN
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Sahm
Crude Oil Falls 4%; US Consumer Sentiment Rises In June - Sahm
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? - AOL.com
Omeros Corp (OMER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omeros (OMER) Faces Regulatory Setback for Narsoplimab Approval - GuruFocus
Omeros stock crashes on regulatory setback: buy the dip? - Invezz
Finanzdaten der Omeros Corp-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
Omeros Corp-Aktie (OMER) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cable Thomas J. | Director |
May 22 '26 |
Sale |
11.61 |
7,500 |
87,039 |
35,067 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):